Table 36Results of Threshold Analysis Regarding PML Associated With Natalizumab

PML rateMortality rateTotal CostTotal QALYsVersus Glatiramer
Acetate
ICUR
0.00%18.5%$482,69211.585$514,201
0.15% (base case)18.5%$482,43611.580$522,472
0.20%18.5%$482,34811.578$525,377
1.00%18.5%$480,98311.549$575,626
0.15%0%$482,69211.585$514,201
0.15%10%$482,55011.582$518,755
0.15%18.50% (base case)$482,43611.580$522,472
0.15%30%$482,29311.577$527,229

ICUR = incremental cost-utility ratio; PML = progressive multifocal leukoencephalopathy; QALY = quality-adjusted life-year.

From: 4, RESULTS

Cover of Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis
Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis [Internet].
CADTH Therapeutic Review, No. 1.2B.
Copyright © CADTH March 2013.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.